Ñî¹óåú´«Ã½Ò•îl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • Ñî¹óåú´«Ã½Ò•îl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • When Immigrant Parents Are Arrested
  • Sandwiched Caregivers
  • Medical Debt
  • Rising Health Costs
  • Ivermectin Sales

WHAT'S NEW

  • When Immigrant Parents Are Arrested
  • Sandwiched Caregivers
  • Medical Debt
  • Rising Health Costs
  • Ivermectin Sales

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Aug 5 2020

Full Issue

Perspectives: Insulin, Trump Hype, US Drug-Pricing System

Read recent commentaries about drug-cost issues.

President Donald Trump sometimes speaks as if a hoped-for result is the same as a done-deal. A day after he signed an executive order on insulin at the end of July, he took a victory lap on Twitter. "Nothing like this has ever been done before because Big Pharma, with its vast power, would not let it happen," he said in his July 25 tweet. "Expensive insulin went from big dollars to virtual pennies." (Jon Greenberg, 8/3)

President Donald Trump is making grandiose claims about slashing drug prices and the efficacy of a treatment for COVID-19 that don’t hold up to reality. In a tweet Sunday, he asserts that he will reduce drug prices by at least 50%. That’s highly unlikely. Measures announced last month by the president will take time to roll out and their effects are uncertain. They also have been less ambitious than a plan by Speaker Nancy Pelosi that passed the House. (Calvin Woodward and Hope Yen, 8/2)

It was supposed to be the year of fixing the U.S. drug pricing system. Instead, the novel coronavirus pandemic is preoccupying Congress, making it nearly impossible for even President Trump to force attention on the issue ahead of the November election.Congress is negotiating another massive coronavirus relief bill, yet it’s devoid of any broad measures to lower prescription drug prices. Lobbyists and advocates acknowledge drug pricing legislation has sunk low on the list of priorities for lawmakers, even after the powerful Senate Finance Committee and the House passed in 2019 measures aimed at reducing drug prices and momentum seemed to be building during this election year toward a deal with the White House. (Paige Winfield Cunningham, 7/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, June 18
  • Wednesday, June 17
  • Tuesday, June 16
  • Monday, June 15
  • Friday, June 12
  • Thursday, June 11
More Morning Briefings
RSS Feeds
  • Ñî¹óåú´«Ã½Ò•îl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF